20/20 Biolabs Inc. (AIDX) vs PharmaCyte Biotech, Inc. (PMCB)

A side-by-side comparison of 20/20 Biolabs Inc. and PharmaCyte Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
20/20 Biolabs Inc. logo
AIDX
20/20 Biolabs Inc.
$4M
$0.35HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PharmaCyte Biotech, Inc. logo
PMCB
PharmaCyte Biotech, Inc.
$5M
$0.42HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AIDX vs PMCB

growth of $100 · dividends reinvested · last 1y
AIDX -98.5% (-98.5%/yr)PMCB -40.1% (-40.1%/yr)PMCB compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100$1$60
AIDX PMCB

AIDX vs PMCB: by the numbers

  • •PMCB is the larger company ($5M vs $4M market cap).
  • •Both run net losses; PMCB's is the smaller (0.00% vs -285.00% net margin).

Metrics side by side

Valuation

MetricAIDXPMCB
P/S ratio2.12N/A
P/B ratio2.660.16

Profitability

MetricAIDXPMCB
Gross margin31.52%0.00%
Operating margin-162.87%0.00%
Net margin-285.00%0.00%
ROE-184.04%-54.15%
ROIC-116.89%-19.51%

Growth (annualized)

MetricAIDXPMCB
Revenue CAGR (5Y)-2.58%N/A
Total return CAGR (5Y)N/A-33.59%

Go deeper

Full AIDX analysisFull PMCB analysisInteractive comparison tool

Dig into the metrics

20/20 Biolabs ROEPharmaCyte Biotech ROE20/20 Biolabs operating marginPharmaCyte Biotech operating margin20/20 Biolabs revenue growthPharmaCyte Biotech revenue growth20/20 Biolabs free cash flowPharmaCyte Biotech free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.